AIM ImmunoTech Inc. (AIM)
NYSEAMERICAN: AIM · Real-Time Price · USD
0.2660
0.00 (0.00%)
At close: Jul 14, 2026, 4:00 PM EDT
0.2665
+0.0005 (0.19%)
After-hours: Jul 14, 2026, 8:00 PM EDT
AIM ImmunoTech Revenue
AIM ImmunoTech had revenue of $22.00K in the quarter ending March 31, 2026, with 37.50% growth. This brings the company's revenue in the last twelve months to $73.00K, down -27.72% year-over-year. In the year 2025, AIM ImmunoTech had annual revenue of $88.00K, down -48.24%.
Revenue (ttm)
$73.00K
Revenue Growth
-27.72%
P/S Ratio
62.49
Revenue / Employee
$4,476
Employees
21
Market Cap
5.87M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 88.00K | -82.00K | -48.24% |
| Dec 31, 2024 | 170.00K | -32.00K | -15.84% |
| Dec 31, 2023 | 202.00K | 61.00K | 43.26% |
| Dec 31, 2022 | 141.00K | 6.00K | 4.44% |
| Dec 31, 2021 | 135.00K | -28.00K | -17.18% |
| Dec 31, 2020 | 163.00K | 23.00K | 16.43% |
| Dec 31, 2019 | 140.00K | -227.00K | -61.85% |
| Dec 31, 2018 | 367.00K | -70.00K | -16.02% |
| Dec 31, 2017 | 437.00K | 345.00K | 375.00% |
| Dec 31, 2016 | 92.00K | -41.00K | -30.83% |
| Dec 31, 2015 | 133.00K | -64.00K | -32.49% |
| Dec 31, 2014 | 197.00K | 47.00K | 31.33% |
| Dec 31, 2013 | 150.00K | -63.00K | -29.58% |
| Dec 31, 2012 | 213.00K | 52.00K | 32.30% |
| Dec 31, 2011 | 161.00K | 26.00K | 19.26% |
| Dec 31, 2010 | 135.00K | 24.00K | 21.62% |
| Dec 31, 2009 | 111.00K | -154.00K | -58.11% |
| Dec 31, 2008 | 265.00K | -794.00K | -74.98% |
| Dec 31, 2007 | 1.06M | 126.00K | 13.50% |
| Dec 31, 2006 | 933.00K | -150.00K | -13.85% |
| Dec 31, 2005 | 1.08M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Xenetic Biosciences | 3.19M |
| BioAtla | 2.00M |
| Addex Therapeutics | 136.51K |
| Silo Pharma | 72.10K |
| Pulmatrix | 3.00K |
AIM News
- 7 days ago - AIM ImmunoTech Announces Release of New CEO Corner Segment Highlighting Growing Momentum Across Pancreatic Cancer Program - GlobeNewsWire
- 19 days ago - AIM ImmunoTech Proxy statement: Proxy filing - Filings
- 20 days ago - AIM ImmunoTech Accelerates Toward Potential Pivotal Pancreatic Cancer Program as Ampligen Continues to Advance Through Key Clinical Milestones - GlobeNewsWire
- 21 days ago - AIM Sports Group's National SoCal Cup ‘The Showcase' Event Serves Up a Weekend of New Experiences - Business Wire
- 22 days ago - AIM ImmunoTech to Present in the Webull Corporate Connect Webinar Series - GlobeNewsWire
- 26 days ago - AIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic Cancer - GlobeNewsWire
- 26 days ago - AIM ImmunoTech Registration statement: Registration filing - Filings
- 27 days ago - AIM Talks China 2026 Convenes in Guangzhou, Advancing Strategic Partnerships and Cross Border Investment Across the Greater Bay Area - GlobeNewsWire